Voloridge Investment Management
SNDX icon

Voloridge Investment Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Voloridge Investment Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-79,071
Closed -$1.05M – 1353
2024
Q4 		$1.05M Buy
+79,071
New +$1.35M ﹤0.01% 1034
2022
Q4 		– Sell
-21,563
Closed -$518K – 1626
2022
Q3 		$518K Buy
21,563
+11,141
+107% +$250K ﹤0.01% 1259
2022
Q2 		$201K Sell
10,422
-110,609
-91% -$1.84M ﹤0.01% 1381
2022
Q1 		$2.1M Buy
121,031
+107,202
+775% +$1.81M 0.01% 933
2021
Q4 		$303K Buy
+13,829
New +$256K ﹤0.01% 1471

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Voloridge Investment Management's SNDX Position: Q1 2025 in Review

Voloridge Investment Management sold out of Syndax Pharmaceuticals (SNDX) in Q1 2025, closing a stake of 79,071 shares — an estimated $1.05M sold.

Voloridge Investment Management first reported a position in SNDX in Q4 2021 and held it in 5 quarters. The position peaked at $2.1M in Q1 2022. 218 funds tracked by Wall St. Rank hold SNDX as of Q1 2025.

  • Voloridge Investment Management reported no remaining Syndax Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Voloridge Investment Management sold 79,071 Syndax Pharmaceuticals shares in Q1 2025, an estimated $1.05M.
  • Voloridge Investment Management first reported a position in Syndax Pharmaceuticals in Q4 2021 and held it in 5 quarters.
  • Voloridge Investment Management's Syndax Pharmaceuticals position peaked at $2.1M in Q1 2022.
  • 218 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2025.

Based on Voloridge Investment Management's 13F filing for Q1 2025, filed 15 May 2025.